- 著者
- Hiroyuki Hayakawa Hiromichi Tanaka Naoko Itoh Masako Nakajima Tadashi Miyasaka Kentaro Yamaguchi Yoichi Iitaka
- 出版者
- The Pharmaceutical Society of Japan
- 雑誌
- Chemical and Pharmaceutical Bulletin (ISSN:00092363)
- 巻号頁・発行日
- vol.35, no.6, pp.2605-2608, 1987-06-25 (Released:2009-10-19)
- 参考文献数
- 26
- 被引用文献数
- 30 43
The reaction of organolithium, Grignard, and organoaluminum reagents with 2'- and 3'-ketouridine derivatives was examined. For the reaction of 2', 5'-bis-0- (tert-butyldimethylsilyl) -3'-ketouridine, both organolithiums and organoaluminums seem to be practically useful. But only organoaluminums gave satisfactory yields in the reaction of 3', 5'-0- (tetraisopropyldisiloxan-1, 3-diyl) -2'-ketouridine.
- 著者
- Junya Hashizume Norihide Higuchi Kayoko Sato Yukinobu Kodama Noriko Matsunaga Toshiaki Sakamoto Kentaro Yamaguchi Tadahiro Nakamura Takashi Kitahara Hitoshi Sasaki
- 出版者
- 公益社団法人日本薬学会
- 雑誌
- Biological and Pharmaceutical Bulletin (ISSN:09186158)
- 巻号頁・発行日
- vol.39, no.4, pp.611-614, 2016-04-01 (Released:2016-04-01)
- 参考文献数
- 21
Antiemetic prophylaxis with aprepitant, a 5-hydroxytryptamine3 (5-HT3) receptor antagonist and dexamethasone is recommended for patients receiving intravenous cisplatin chemotherapy. Whether the same antiemetic regime is superior for hepatic transcatheter arterial infusion chemotherapy with cisplatin (CDDP-TAI) is unknown. We conducted a retrospective study of antiemetic prophylaxis protection against chemotherapy-induced nausea and vomiting (CINV) in CDDP-TAI at Nagasaki University Hospital. The rate of complete response (CR) to antiemetics in the acute (<24 h) and delayed phases (24–120 h) was measured. Twenty-four patients were treated with a 5-HT3 receptor antagonist (granisetron or azasetron) and dexamethasone on the day of chemotherapy (day 1 only). There was a significant difference between the CR rates in the acute and delayed phases, 91.6, and 69.7%, respectively. Combination of a 5-HT3 antagonist and dexamethasone on day 1 is effective against acute CINV, but not delayed CINV during CDDP-TAI. These results may help guide the management of nausea and vomiting during CDDP-TAI to achieve better tolerance and compliance for fewer interventions and increased favorable therapeutic outcomes.